Antisauvagine-30 TFA
Based on 4 publication(s) in Google Scholar
Antisauvagine-30 TFA (aSvg-30 TFA) is a potent, highly selective and competitive CRF2 receptor peptidic antagonist. Antisauvagine-30 TFA exhibits a Kd of 1.4 nM and 150 nM for mCRFR2β and CRFR1, respectively.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.64%
- Formule: C161H274N48O46S·xC2HF3O2
- Masse moléculaire:3650.26 (free base)
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Antisauvagine-30 TFA
More
Activité biologique
Kd: 1.4 nM (mCRFR2β), 150 nM (CRFR1).
Antisauvagine-30 (aSvg-30) prevents stress-enhanced fear conditioning and Mek-1/2-dependent activation of Erk-1/2 and p90Rsk-1. Antisauvagine-30 (aSvg-30) did not affect the phosphorylation of the PKA regulatory subunit II of stressed mice[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Antisauvagine-30 (aSvg-30) injected i.c.v. elicits a significant anxiogenic effect[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nine-week-old male BALB/c mice[2].
-
Dosage:400 ng/0.5 μl per mouse.
-
Administration:Administered bilaterally by a microinjector (intrahippocampal (i.h.) injection).
-
Result:Prevented the stress-induced enhancement of fear conditioning.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 3650.26 (free base)
-
Formule C161H274N48O46S·xC2HF3O2
-
Color White to off-white
-
SMILES
O=C(N[C@@H](CC1=CNC=N1)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCSC)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H]([C@@H](C)CC)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@@H](CC2=CC=CC=C2)N.O=C(O)C(F)(F)F.[x]
-
Synonyms
aSvg-30 TFA
-
Sequence
{DPhe}-His-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH2
-
Sequence Shortening
{DPhe}-HLLRKMIEIEKQEKEKQQAANNRLLLDTI-NH2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
PVNCRF Neurons Regulate Migraine-Like Allodynia by Activating CRFR2 on Spinal Trigeminal Caudalis Glutamatergic Neurons. [Abstract]2026 Feb 28:e20530. PMID: 41762709 -
Pain
Mast cell corticotropin-releasing factor receptor 1 contributes to pancreatic cancer pain via mitogen-activated protein kinase/sphingosine kinases type 1 signaling. [Abstract]2026 Apr 1;167(4):962-975. PMID: 41615309 -
Ann Med
Corticotropin-releasing hormone inhibits autophagy by suppressing PTEN to promote apoptosis in dermal papilla cells. [Abstract]2025 Dec;57(1):2490823. PMID: 40219757 -
Sci Rep
Spinal CRH facilitates the micturition reflex via the CRH2 receptor in rats with normal bladder and bladder outlet obstruction. [Abstract]2025 Jan 29;15(1):3604. PMID: 39875474
Solvant et solubilité
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 25 mg/mL (Need ultrasonic)
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Brauns O, et al. Pharmacological and chemical properties of astressin, antisauvagine-30 and alpha-helCRF: significance for behavioral experiments. Neuropharmacology. 2001 Sep;41(4):507-16. [Content Brief]
[2]. Sananbenesi F, et al. Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotropin-releasing factor receptor 2: a possible link between stress and fear memory. J Neurosci. 2003 Dec 10;23(36):11436-43. [Content Brief]
[3]. Radulovic J, et al. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci. 1999 Jun 15;19(12):5016-25. [Content Brief]
[4]. Klaus Eckart, et al. Action of CRF and its analogs. Current Medicinal Chemistry, 1999, 6, 1035-1053.
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)